Public procurement notice: Contract Notice
Published: 2020-08-21
Buyer: Türkiye Cumhuriyeti Sağlık Bakanlığı
Country: TR
Contract type: Services
Procedure: Open procedure
CPV classification: 32441100 | 32441300 | 33000000 | 33100000 | 33190000
Estimated value: 4620000 EUR
Submission deadline: 2020-11-13
Award criteria: The most economic tender
EU fund: Horizon Europe

Technical requirements: Pre-commercial Procurement of innovative ICT-enabled Monitoring to Improve Health Status and Optimise Hypertension Care
The procurement aims to trigger new solutions to be developed and tested to address the challenge of the rising incidence of hypertension and the need for more effective management by empowering patients and the healthcare professionals involved in their care.
The procurement should address the procurers' unmet needs relating to different aspects (building blocks) of hypertension care: early detection and prevention, healthier lifestyle and nutrition, optimised drug therapy and improving treatment adherence, use of devices and remote monitoring, personalised decision support, interoperability and integration, quality and outcome reporting, patient-professional collaboration and co-ordination, training and education.
Testing is expected to take place in Istanbul (Turkey); Naples (Italy); Jämtland Härjedalen (Sweden); Zagreb (Croatia); Milan (Italy).
The procurement will take the form of a pre-commercial procurement (PCP) under which R&D service contracts will be awarded to R&D providers in parallel in a phased approach. This will make it possible to compare competing alternative solutions. Each selected operator will be awarded a framework agreement that covers three R&D phases. For each phase, a specific contract will be concluded with the selected operators. The three phases are: solution design, prototype development, original development and validation and testing of a limited volume of first products or services. After each phase, intermediate evaluations will be carried out to select the best of the competing solutions. The contractors with the best value-for-money solutions will be offered a specific contract for the next phase.
The selected operators will retain ownership of the intellectual property rights (IPRs) that they generate during the PCP and will be able to use them to exploit the full market potential of the developed solutions.
This procurement receives funding from the European Union’s Horizon 2020 Research and Innovation Programme, under grant agreement No 856698 — HSMonitor (https://hsmonitor-pcp.eu/). The EU has given a grant for this procurement, but is not participating as a contracting authority in the procurement.
HSMonitor carried out a series of open market consultation (OMC) events in the period 25 March 2020-15 June 2020 to inform the specifications of the tender. All materials and recordings are available at https://hsmonitor-pcp.eu/. Participation in the OMC events is not a prerequisite for submitting a tender for this call.
The PCP procurement is exempted from the WTO Government Procurement Agreement (GPA), the EU public procurement directives and the national laws that implement them (because it concerns the procurement of R&D services where the benefits do not accrue exclusively to the contracting authority for its use in the conduct of its own affairs).


Award value: 4620000